XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.29M | 2.32M | 2.41M | 2.39M | 2.35M |
| Depreciation & Amortization | 111.00K | 117.10K | 115.40K | 106.00K | 105.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.79M | 2.62M | 2.84M | 3.34M | 3.90M |
| Operating Income | -2.79M | -2.62M | -2.84M | -3.34M | -3.90M |
| Income Before Tax | -993.10K | -3.31M | -736.60K | -1.48M | -3.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.99 | -3.31 | -0.74 | -1.48 | -3.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -993.10K | -3.31M | -736.60K | -1.48M | -3.35M |
| EBIT | -2.79M | -2.62M | -2.84M | -3.34M | -3.90M |
| EBITDA | -3.08M | -2.89M | -2.74M | -3.24M | -3.81M |
| EPS Basic | -0.29 | -1.35 | -0.04 | -0.50 | -1.41 |
| Normalized Basic EPS | -0.18 | -0.84 | -0.02 | -0.31 | -0.88 |
| EPS Diluted | -0.30 | -1.35 | -0.04 | -0.50 | -1.41 |
| Normalized Diluted EPS | -0.18 | -0.84 | -0.02 | -0.31 | -0.88 |
| Average Basic Shares Outstanding | 12.82M | 11.51M | 10.24M | 9.33M | 8.43M |
| Average Diluted Shares Outstanding | 12.82M | 11.51M | 10.24M | 9.33M | 8.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |